A new clinical trial update was registered on November 5, 2026, involving androgen deprivation therapy (ADT), a category that includes goserelin. The study, titled "A Study to Learn How Well a Combination of Darolutamide and Androgen Deprivation Therapy (ADT) Works as a Treatment Before Surgery for Men Who Have High-risk Localized Prostate Cancer," is listed under identifier NCT07450599.
The trial is currently in Phase 2 and has a status of recruiting. It is designed to evaluate the combination of darolutamide and ADT administered before surgery in men with high-risk localized prostate cancer.
No results have been posted for this trial at this time. The current update reflects only the trial's recruitment status, phase, and title as registered. No efficacy or safety outcomes have been reported in connection with this study.
Goserelin is an approved therapy and may be used as one form of ADT in treatment regimens such as the one being studied in this trial. Readers interested in background on this compound can consult the goserelin compound overview for additional context.